144 related articles for article (PubMed ID: 20420387)
41. Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors.
Cole DC; Asselin M; Brennan A; Czerwinski R; Ellingboe JW; Fitz L; Greco R; Huang X; Joseph-McCarthy D; Kelly MF; Kirisits M; Lee J; Li Y; Morgan P; Stock JR; Tsao DH; Wissner A; Yang X; Chaudhary D
J Med Chem; 2008 Oct; 51(19):5958-63. PubMed ID: 18783200
[TBL] [Abstract][Full Text] [Related]
42. Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole.
Wang T; Duffy JP; Wang J; Halas S; Salituro FG; Pierce AC; Zuccola HJ; Black JR; Hogan JK; Jepson S; Shlyakter D; Mahajan S; Gu Y; Hoock T; Wood M; Furey BF; Frantz JD; Dauffenbach LM; Germann UA; Fan B; Namchuk M; Bennani YL; Ledeboer MW
J Med Chem; 2009 Dec; 52(24):7938-41. PubMed ID: 20014869
[TBL] [Abstract][Full Text] [Related]
43. Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
Bindi S; Fancelli D; Alli C; Berta D; Bertrand JA; Cameron AD; Cappella P; Carpinelli P; Cervi G; Croci V; D'Anello M; Forte B; Giorgini ML; Marsiglio A; Moll J; Pesenti E; Pittalà V; Pulici M; Riccardi-Sirtori F; Roletto F; Soncini C; Storici P; Varasi M; Volpi D; Zugnoni P; Vianello P
Bioorg Med Chem; 2010 Oct; 18(19):7113-20. PubMed ID: 20817473
[TBL] [Abstract][Full Text] [Related]
44. Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives.
Cho TP; Dong SY; Jun F; Hong FJ; Liang YJ; Lu X; Hua PJ; Li LY; Lei Z; Bing H; Ying Z; Qiong LF; Bei FB; Guang LL; Shen GA; Hong SG; Hong SW; Tai MX
J Med Chem; 2010 Nov; 53(22):8140-9. PubMed ID: 21028894
[TBL] [Abstract][Full Text] [Related]
45. Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin.
Hirota T; Lipp JJ; Toh BH; Peters JM
Nature; 2005 Dec; 438(7071):1176-80. PubMed ID: 16222244
[TBL] [Abstract][Full Text] [Related]
46. Aurora kinases: new targets for cancer therapy.
Carvajal RD; Tse A; Schwartz GK
Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
[TBL] [Abstract][Full Text] [Related]
47. Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.
Menichincheri M; Albanese C; Alli C; Ballinari D; Bargiotti A; Caldarelli M; Ciavolella A; Cirla A; Colombo M; Colotta F; Croci V; D'Alessio R; D'Anello M; Ermoli A; Fiorentini F; Forte B; Galvani A; Giordano P; Isacchi A; Martina K; Molinari A; Moll JK; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pillan A; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Vianello P; Volpi D; Santocanale C; Vanotti E
J Med Chem; 2010 Oct; 53(20):7296-315. PubMed ID: 20873740
[TBL] [Abstract][Full Text] [Related]
48. Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.
Anderson K; Lai Z; McDonald OB; Stuart JD; Nartey EN; Hardwicke MA; Newlander K; Dhanak D; Adams J; Patrick D; Copeland RA; Tummino PJ; Yang J
Biochem J; 2009 May; 420(2):259-65. PubMed ID: 19284385
[TBL] [Abstract][Full Text] [Related]
49. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
Wunderlich A; Fischer M; Schlosshauer T; Ramaswamy A; Greene BH; Brendel C; Doll D; Bartsch D; Hoffmann S
Cancer Sci; 2011 Apr; 102(4):762-8. PubMed ID: 21214672
[TBL] [Abstract][Full Text] [Related]
51. Aurora-B associated protein phosphatases as negative regulators of kinase activation.
Sugiyama K; Sugiura K; Hara T; Sugimoto K; Shima H; Honda K; Furukawa K; Yamashita S; Urano T
Oncogene; 2002 May; 21(20):3103-11. PubMed ID: 12082625
[TBL] [Abstract][Full Text] [Related]
52. Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor.
Coumar MS; Tsai MT; Chu CY; Uang BJ; Lin WH; Chang CY; Chang TY; Leou JS; Teng CH; Wu JS; Fang MY; Chen CH; Hsu JT; Wu SY; Chao YS; Hsieh HP
ChemMedChem; 2010 Feb; 5(2):255-67. PubMed ID: 20039358
[TBL] [Abstract][Full Text] [Related]
53. SAR and evaluation of novel 5H-benzo[c][1,8]naphthyridin-6-one analogs as Aurora kinase inhibitors.
Karra S; Xiao Y; Chen X; Liu-Bujalski L; Huck B; Sutton A; Goutopoulos A; Askew B; Josephson K; Jiang X; Shutes A; Shankar V; Noonan T; Garcia-Berrios G; Dong R; Dhanabal M; Tian H; Wang Z; Clark A; Goodstal S
Bioorg Med Chem Lett; 2013 May; 23(10):3081-7. PubMed ID: 23570792
[TBL] [Abstract][Full Text] [Related]
54. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
[TBL] [Abstract][Full Text] [Related]
55. Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase.
Yang H; Burke T; Dempsey J; Diaz B; Collins E; Toth J; Beckmann R; Ye X
FEBS Lett; 2005 Jun; 579(16):3385-91. PubMed ID: 15922328
[TBL] [Abstract][Full Text] [Related]
56. Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity.
Coumar MS; Leou JS; Shukla P; Wu JS; Dixit AK; Lin WH; Chang CY; Lien TW; Tan UK; Chen CH; Hsu JT; Chao YS; Wu SY; Hsieh HP
J Med Chem; 2009 Feb; 52(4):1050-62. PubMed ID: 19140666
[TBL] [Abstract][Full Text] [Related]
57. Validating Aurora B as an anti-cancer drug target.
Girdler F; Gascoigne KE; Eyers PA; Hartmuth S; Crafter C; Foote KM; Keen NJ; Taylor SS
J Cell Sci; 2006 Sep; 119(Pt 17):3664-75. PubMed ID: 16912073
[TBL] [Abstract][Full Text] [Related]
58. Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.
Chen Z; Venkatesan AM; Dehnhardt CM; Ayral-Kaloustian S; Brooijmans N; Mallon R; Feldberg L; Hollander I; Lucas J; Yu K; Kong F; Mansour TS
J Med Chem; 2010 Apr; 53(8):3169-82. PubMed ID: 20334367
[TBL] [Abstract][Full Text] [Related]
59. An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins.
Myrianthopoulos V; Magiatis P; Ferandin Y; Skaltsounis AL; Meijer L; Mikros E
J Med Chem; 2007 Aug; 50(17):4027-37. PubMed ID: 17665890
[TBL] [Abstract][Full Text] [Related]
60. Benzo[e]pyridoindoles, novel inhibitors of the aurora kinases.
Hoang TM; Favier B; Valette A; Barette C; Nguyen CH; Lafanechère L; Grierson DS; Dimitrov S; Molla A
Cell Cycle; 2009 Mar; 8(5):765-72. PubMed ID: 19221479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
